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lieved to have received a purple-dyed robe from Her-CDK versus GSK-3 Inhibition:
akles and decreed that the rulers of Phoenicia shoulda Purple Haze No Longer? wear this color as a royal symbol, hence the name Tyrian
purple. Pharmacological properties of indirubins have
also long been known, and indirubin (Figure 1, 1a) is a
constituent of a traditional Chinese cancer medicine [8].
Their antiproliferative properties may in part be due to
the fact that indirubins inhibit the phylogenetically and
The ubiquitous ATP binding site offers a global target structurally closely related cyclin-dependent kinases
for protein kinase inhibitors. The corollary is that mo- (CDK) and the glycogen synthase kinases-3 (GSK-3). In
lecular selectivity with such agents may be difficult to fact, many compounds discovered as CDK inhibitors
achieve and ascertain. A relevant example is dis- are known to block GSK-3 function as well [9].
cussed in terms of design and biomedical rationale. Meijer et al. present crystal structures of indirubin-3-
oxime (Figure 1, 1b) and its 6-bromo derivative Figure
1, 1c) in complex with CDK5 and GSK-3, respectively
[3]. The latter compound is16-fold selective for GSK-3Over the last two decades, the structural biology of
compared to CDKs 2 and 5 (which are structurally ex-protein kinases as well as the design of their inhibitors
tremely similar [10]). The des-bromo compound (Figurehas become of great interest to both academic and
1, 1b), on the other hand, is only about 5-fold selectivepharmaceutical scientists. Because the ATP binding site
for GSK-3, and the 5-sulfonate analog (Figure 1, 1d)in kinases is inherently amenable to blocking with drug-
is about 4-fold selective for CDKs [11]. The structureslike small molecules, the discovery and development of
presented show that the selectivity gain associated withkinase inhibitors is now being pursued for every imagin-
the bromo substituent on C6 of the indirubin scaffoldable therapeutic indication [1]. Furthermore, since the
correlates with one of the main structural differencesprotein kinases, of which some 500 have been identified
between GSK-3 and CDK2/5, viz. the so-called gate-in the human genome [2], are the key players in the
keeper residue often exploited for the design of kinaseregulation of all biochemical pathways, they appear to
selectivity in ligands [12]. In nine of the ten known CDKrepresent excellent targets for a new generation of
isoforms, this residue is Phe (F80 in CDK2), whereasmechanism-based drugs. However, unpredictable phar-
Leu (L132) is found in GSK-3. The authors argue that
macology and, ultimately, unforeseen patient side ef-
because of the smaller aliphatic side chain in that posi-
fects might be expected with therapeutic agents targeting
tion, GSK-3 is better able to accommodate the 6-bromo
any conserved recognition site, i.e. the ATP binding group and that indirubin C5/6 substitution studies may
pocket, which is highly conserved not only in kinases give rise to future analogs with increased selectivity [3].
but also in many other mononucleotide binding proteins. In fact, another very recently published study with the
The challenge with kinase inhibitors is thus how to thiazole-methoxybenzyl-thiourea compound 2 (Figure
achieve selectivity. A paper in this issue of Chemistry & 1), which is truly selective for GSK-3 versus CDKs [13],
Biology by Meijer et al. addresses this very point [3]. confirms this hypothesis. In that case, it was found that
The authors take us on an historical excursion regard- the thiazole nitro substituent occupies the subsite adja-
ing the discovery of indirubins (Figure 1, 1). These com- cent to L132 in GSK-3, which is not accessible in CDKs
pounds confer the characteristic purple color to natural because of the larger aromatic Phe side chain. Addition-
indigo dyes. According to legend, purple dye was first ally, the anisole system in compound 2 was observed
discovered by Herakles, when he observed that his to bind at the entrance to the ATP binding site in GSK-3
dog’s mouth was stained purple after chewing on snails in the vicinity of R141, which is salt bridged with E137.
In CDK2 and probably also in CDK5, a correspondingalong the Levantine coast. King Phoenix of Tyre is be-
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Figure 1. Structures and Kinase Binding
Modes of CDK/GSK-3 Inhibitors
The positions of the conserved H-bond pair
with the kinase hinge region, i.e., V135 (in
GSK-3), are indicated. The 3D structure
shows the binding mode of 1d constructed
from alignments between Protein Data Bank
ID codes 1E9H (complex of 1d with CDK2 [4];
purple side chains), 1I09 (GSK-3 [5]), 1QMZ
(activated CDK2-cyclin A complex [6]; pink
side chains), and 1Q41 (complex of 1b with
GSK-3 [7], not shown).
site is not present because the residue equivalent to sumably, this group occupies a similar subsite as the
anisole portion in 2. In Figure 2, which gives an overallR141, i.e., K89, points into the ATP pocket and in fact
interacts with I10 in the Gly-rich loop of the N-terminal comparison of the shape of the ATP binding sites in
GSK-3 and CDK2, the major difference in the entrancekinase lobe in the activated CDK2/cyclin A complex.
Analysis of the SARs and structural studies with 5-aryl- to the ATP binding pocket is evident.
Yet another recent structural study using inhibitors ofpyrazolo[3,4-b]pyridazines provide a similar picture [14].
Here, the positions of the fluorine atoms in e.g., the varying selectivity also concludes that there are numer-
ous subsites of the GSK-3 ATP binding pocket that canhighly GSK-3-selective analog compound 3 (Figure 1)
were observed in the vicinity of the GSK-3 L132 side be exploited for the design of selective inhibitors [7].
The fact that methylation or acetylation of the oximechain and are associated with both potency and selec-
tivity for GSK-3. Again, an additional determinant for function in compound 1c further increased GSK-3 selec-
tivity [3] is in line with this finding.selectivity was seen; this concerns the acyl portion of
the amide, i.e., CH2-piperidine-ethyl in compound 3. Pre- CDK-inhibitory drugs are sought predominantly as an-
Figure 2. ATP Binding Sites in CDK2 and GSK-3
A view into the ATP binding pockets of CDK2 (A) and GSK-3 (B) constructed from alignments between Protein Data Bank ID codes 1QMZ
and 1I09.
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trained to think of structures in this way from the mo-RNA as Multitude/RNA as One
tionless, indispensable polychromes that illustrate the
conclusions of structural biologists’ experiments. How-
ever, the huge energetic penalty rendered for unpaired
charges implies that RNA molecules are always electri-In the configurations formed by RNA and its ions there
cally neutral. Therefore, RNAs are inevitably accompa-are structural possibilities not yet realized; some are
hinted at in new work on the binding of an amino acid nied by ions, about one ionic charge per nucleotide
analog. phosphate. So, for many purposes, RNA is better illus-
trated as a fluctuating crowd of particles. Magnesium
is more influential than potassium because the electricalRNA surely means different things to different biologists,
neutrality generated by localizing a single magnesiumbut molecules are usually thought of as unitary objects,
as explicit as a mountain or a building. We have been ion frees two potassium ions, yielding an entropic ad-
